ZIM
ADAP

Zacks Investment Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Zacks Investment Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-15,418
Closed -$103K – 518
2017
Q4 		$103K Buy
+15,418
New +$119K ﹤0.01% 555

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Zacks Investment Management's ADAP Position: Q1 2018 in Review

Zacks Investment Management sold out of Adaptimmune Therapeutics (ADAP) in Q1 2018, closing a stake of 15,418 shares — an estimated $103K sold.

Zacks Investment Management first reported a position in ADAP in Q4 2017 and held it in 1 quarter. The position peaked at $103K in Q4 2017. 76 funds tracked by Wall St. Rank hold ADAP as of Q1 2018.

  • Zacks Investment Management reported no remaining Adaptimmune Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Zacks Investment Management sold 15,418 Adaptimmune Therapeutics shares in Q1 2018, an estimated $103K.
  • Zacks Investment Management first reported a position in Adaptimmune Therapeutics in Q4 2017 and held it in 1 quarter.
  • Zacks Investment Management's Adaptimmune Therapeutics position peaked at $103K in Q4 2017.
  • 76 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2018.

Based on Zacks Investment Management's 13F filing for Q1 2018, filed 14 May 2018.